Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is AstraZeneca Paying Too Much for Alexion?

TheMotleyFool

0 0

Is AstraZeneca Paying Too Much for Alexion?

Earlier this month, AstraZeneca (NASDAQ: AZN) announced plans to acquire rare-disease expert Alexion (NASDAQ: ALXN) for $39 billion. In this video from Motley Fool Live, recorded on Dec. 14, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss what AstraZeneca is getting in the deal. They also debate whether the U.K.-based drugmaker is overpaying for access to Alexion's repertory of commercial drugs and drug candidates.

Source Fool.com

Like: 0

AZN

Share